FFO
NBIX icon

Fortitude Family Office’s Neurocrine Biosciences NBIX Stock Holding History

Fortitude Family Office’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3K Buy
174
+123
+241% +$18.2K 0.01% 418
2026
Q1 		$6.72K Buy
51
+31
+155% +$4.11K ﹤0.01% 810
2025
Q4 		$2.84K Sell
20
-1
-5% -$145 ﹤0.01% 1035
2025
Q3 		$2.95K Buy
21
+6
+40% +$813 ﹤0.01% 1036
2025
Q2 		$1.89K Buy
+15
New +$1.72K ﹤0.01% 1228
2025
Q1 		– Sell
-6
Closed -$819 – 1242
2024
Q4 		$819 Sell
6
-11
-65% -$1.36K ﹤0.01% 1161
2024
Q3 		$1.96K Buy
17
+8
+89% +$1.1K ﹤0.01% 1008
2024
Q2 		$1.24K Hold
9
– – ﹤0.01% 861
2024
Q1 		$1.24K Hold
9
– – ﹤0.01% 891
2023
Q4 		$1.19K Buy
+9
New +$1.04K ﹤0.01% 930

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fortitude Family Office's NBIX Position: Q2 2026 in Review

Fortitude Family Office increased its Neurocrine Biosciences (NBIX) stake by 241% in Q2 2026, buying an estimated $18.2K and bringing the position to 174 shares worth $29.3K. The position accounts for 0.01% of the portfolio, ranked #418.

Fortitude Family Office first reported a position in NBIX in Q4 2023 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fortitude Family Office held 174 shares of Neurocrine Biosciences worth $29.3K as of Q2 2026.
  • Fortitude Family Office bought 123 Neurocrine Biosciences shares in Q2 2026, an estimated $18.2K.
  • Neurocrine Biosciences made up 0.01% of Fortitude Family Office's portfolio in Q2 2026, its #418 holding.
  • Fortitude Family Office first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 10 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.